Clinical Edge Journal Scan

Breast cancer: Mortality rates remain high beyond 5 years of diagnosis


 

Key clinical point: The risk for breast cancer-specific mortality (BCSM) remains high beyond 5 years. The BCSM rate is significantly higher in hormone receptor (HR)-positive vs. HR-negative women.

Major finding: The overall BCSM rate was 14.9%. Of all BCSM, 54.2% of deaths occurred after 5 years and were significantly higher in HR-positive vs. HR-negative patients ( P less than .001). Among patients with HR-positive and HR-negative breast cancer, independent risk factors for BCSM conditional on having survived 5 years were tumor size, nodal status, age, and year of diagnosis. Among patients with HR-positive status, tumor grade, marital status, and race were also independently associated with the risk for BCSM.

Study details: An observational study of 202,080 women with breast cancer with known HR status diagnosed between 1990 and 2005.

Disclosures: The study did not receive any funding. Some authors received research funding and/or advisory/consulting fees from various sources.

Source: Leone JP. Breast Cancer Res Treat. 2021 Apr 24. doi: 10.1007/s10549-021-06233-4.

Recommended Reading

Optimal Treatment for HR+/HER2- Breast Cancer Patients With Visceral Metastasis
MDedge Hematology and Oncology
New targeted treatments are major advances for HER2-positive breast cancer
MDedge Hematology and Oncology
Endocrine therapy benefits in premenopausal breast cancer differ by molecular risk
MDedge Hematology and Oncology
Trastuzumab deruxtecan-related lung disease in MBC patients can occur anytime in first year
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Breast Cancer June 2021
MDedge Hematology and Oncology
Breast-conserving surgery tops mastectomy
MDedge Hematology and Oncology
Breast cancer: Routine scans can identify heart disease
MDedge Hematology and Oncology
Immediate breast reconstruction delays radiotherapy and increases complication
MDedge Hematology and Oncology
Pertuzumab plus high-dose trastuzumab shows activity in HER-2-positive breast cancer
MDedge Hematology and Oncology
Early breast cancer: Trastuzumab emtansine shows survival benefit regardless of NACT used
MDedge Hematology and Oncology